The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. / Le Heuzey, Jean-Yves; Breithardt, Günter; Camm, John; Crijns, Harry; Dorian, Paul; Kowey, Peter R; Merioua, Ihsen; Prystowsky, Eric N; Schwartz, Peter J; Torp-Pedersen, Christian; Weintraub, William.

In: American Journal of Cardiology, Vol. 105, No. 5, 01.03.2010, p. 687-93.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Le Heuzey, J-Y, Breithardt, G, Camm, J, Crijns, H, Dorian, P, Kowey, PR, Merioua, I, Prystowsky, EN, Schwartz, PJ, Torp-Pedersen, C & Weintraub, W 2010, 'The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation', American Journal of Cardiology, vol. 105, no. 5, pp. 687-93. https://doi.org/10.1016/j.amjcard.2009.10.012

APA

Le Heuzey, J-Y., Breithardt, G., Camm, J., Crijns, H., Dorian, P., Kowey, P. R., Merioua, I., Prystowsky, E. N., Schwartz, P. J., Torp-Pedersen, C., & Weintraub, W. (2010). The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. American Journal of Cardiology, 105(5), 687-93. https://doi.org/10.1016/j.amjcard.2009.10.012

Vancouver

Le Heuzey J-Y, Breithardt G, Camm J, Crijns H, Dorian P, Kowey PR et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. American Journal of Cardiology. 2010 Mar 1;105(5):687-93. https://doi.org/10.1016/j.amjcard.2009.10.012

Author

Le Heuzey, Jean-Yves ; Breithardt, Günter ; Camm, John ; Crijns, Harry ; Dorian, Paul ; Kowey, Peter R ; Merioua, Ihsen ; Prystowsky, Eric N ; Schwartz, Peter J ; Torp-Pedersen, Christian ; Weintraub, William. / The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. In: American Journal of Cardiology. 2010 ; Vol. 105, No. 5. pp. 687-93.

Bibtex

@article{3629c71101da434eb451b17650342baf,
title = "The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation",
abstract = "The REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation (RecordAF) is the first worldwide, 1-year observational, longitudinal study of the management of paroxysmal/persistent atrial fibrillation (AF) in recently diagnosed patients. The study was conducted at 532 sites in 21 countries across Europe, America, and Asia; recruitment was completed in April 2008. The primary objectives were to prospectively assess the therapeutic success and clinical outcomes in rhythm- and rate-control strategies. The study design and patient baseline data are reported. A total of 5,814 patients with AF were registered, and 5,604 were eligible for evaluation. Rhythm- and rate-control strategies were applied to 55% and 45% of patients, respectively, at study inclusion. Rhythm-control patients mainly received class III agents (45%) or beta blockers (51%), except for sotalol, and rate-control patients mainly received beta blockers (72%), except for sotalol, or cardiac glycosides (34%). Patients receiving a rhythm-control strategy were younger, had a lower resting heart rate, were more frequently symptomatic, and were more likely to have recently diagnosed AF or paroxysmal AF compared to patients receiving a rate-control strategy. A rate-control strategy was more common in patients with a history of heart failure or valvular heart disease and persistent AF. Rate-control patients more often had previous electrocardiographic evidence of AF and were not in sinus rhythm at inclusion (p",
author = "{Le Heuzey}, Jean-Yves and G{\"u}nter Breithardt and John Camm and Harry Crijns and Paul Dorian and Kowey, {Peter R} and Ihsen Merioua and Prystowsky, {Eric N} and Schwartz, {Peter J} and Christian Torp-Pedersen and William Weintraub",
note = "Copyright 2010 Elsevier Inc. All rights reserved.",
year = "2010",
month = mar,
day = "1",
doi = "http://dx.doi.org/10.1016/j.amjcard.2009.10.012",
language = "English",
volume = "105",
pages = "687--93",
journal = "Am. J. Cardiol.",
issn = "0002-9149",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation

AU - Le Heuzey, Jean-Yves

AU - Breithardt, Günter

AU - Camm, John

AU - Crijns, Harry

AU - Dorian, Paul

AU - Kowey, Peter R

AU - Merioua, Ihsen

AU - Prystowsky, Eric N

AU - Schwartz, Peter J

AU - Torp-Pedersen, Christian

AU - Weintraub, William

N1 - Copyright 2010 Elsevier Inc. All rights reserved.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - The REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation (RecordAF) is the first worldwide, 1-year observational, longitudinal study of the management of paroxysmal/persistent atrial fibrillation (AF) in recently diagnosed patients. The study was conducted at 532 sites in 21 countries across Europe, America, and Asia; recruitment was completed in April 2008. The primary objectives were to prospectively assess the therapeutic success and clinical outcomes in rhythm- and rate-control strategies. The study design and patient baseline data are reported. A total of 5,814 patients with AF were registered, and 5,604 were eligible for evaluation. Rhythm- and rate-control strategies were applied to 55% and 45% of patients, respectively, at study inclusion. Rhythm-control patients mainly received class III agents (45%) or beta blockers (51%), except for sotalol, and rate-control patients mainly received beta blockers (72%), except for sotalol, or cardiac glycosides (34%). Patients receiving a rhythm-control strategy were younger, had a lower resting heart rate, were more frequently symptomatic, and were more likely to have recently diagnosed AF or paroxysmal AF compared to patients receiving a rate-control strategy. A rate-control strategy was more common in patients with a history of heart failure or valvular heart disease and persistent AF. Rate-control patients more often had previous electrocardiographic evidence of AF and were not in sinus rhythm at inclusion (p

AB - The REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation (RecordAF) is the first worldwide, 1-year observational, longitudinal study of the management of paroxysmal/persistent atrial fibrillation (AF) in recently diagnosed patients. The study was conducted at 532 sites in 21 countries across Europe, America, and Asia; recruitment was completed in April 2008. The primary objectives were to prospectively assess the therapeutic success and clinical outcomes in rhythm- and rate-control strategies. The study design and patient baseline data are reported. A total of 5,814 patients with AF were registered, and 5,604 were eligible for evaluation. Rhythm- and rate-control strategies were applied to 55% and 45% of patients, respectively, at study inclusion. Rhythm-control patients mainly received class III agents (45%) or beta blockers (51%), except for sotalol, and rate-control patients mainly received beta blockers (72%), except for sotalol, or cardiac glycosides (34%). Patients receiving a rhythm-control strategy were younger, had a lower resting heart rate, were more frequently symptomatic, and were more likely to have recently diagnosed AF or paroxysmal AF compared to patients receiving a rate-control strategy. A rate-control strategy was more common in patients with a history of heart failure or valvular heart disease and persistent AF. Rate-control patients more often had previous electrocardiographic evidence of AF and were not in sinus rhythm at inclusion (p

U2 - http://dx.doi.org/10.1016/j.amjcard.2009.10.012

DO - http://dx.doi.org/10.1016/j.amjcard.2009.10.012

M3 - Journal article

VL - 105

SP - 687

EP - 693

JO - Am. J. Cardiol.

JF - Am. J. Cardiol.

SN - 0002-9149

IS - 5

ER -

ID: 34115875